Pages that link to "Q70683632"

The following pages link to Stability of time-tradeoff utilities in survivors of myocardial infarction (Q70683632):

Displaying 44 items.

• Longitudinal and cross sectional assessments of health utility in adults with HIV/AIDS: a systematic review and meta-analysis (Q28081861) (← links)
• The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals (Q28169129) (← links)
• A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease (Q28194877) (← links)
• Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease (Q28200330) (← links)
• Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention (Q28221041) (← links)
• A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment (Q33539961) (← links)
• Costs and benefits of free medications after myocardial infarction (Q33585275) (← links)
• A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention (Q33652803) (← links)
• Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. (Q33689688) (← links)
• Economics of drug treatment: for which patients is it costeffective to lower cholesterol? (Q34417093) (← links)
• Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors (Q34733821) (← links)
• Aspirin for primary prevention of cardiovascular events. (Q34752312) (← links)
• Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. (Q34988073) (← links)
• Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis (Q36062323) (← links)
• The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease (Q36073903) (← links)
• The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease (Q36306581) (← links)
• Cost-effectiveness of Antihypertensive Medication: Exploring Race and Sex Differences Using Data From the REasons for Geographic and Racial Differences in Stroke Study (Q36319556) (← links)
• Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease (Q36836401) (← links)
• Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator (Q36949147) (← links)
• Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men (Q37231429) (← links)
• Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries (Q37292366) (← links)
• Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration (Q39566377) (← links)
• Optimizing Statin Treatment Decisions for Diabetes Patients in the Presence of Uncertain Future Adherence (Q39755456) (← links)
• A model to predict the cost-effectiveness of disease management programs (Q39964946) (← links)
• Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy (Q40260838) (← links)
• Methods and problems in measuring quality of life (Q40494363) (← links)
• Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life (Q40742477) (← links)
• A comparison of two approaches for assessing patient importance weights to conduct an Extended Q-TWiST analysis (Q40798930) (← links)
• Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia (Q41687781) (← links)
• Stability of time trade-off utilities for health states associated with the treatment of prostate cancer (Q46107930) (← links)
• Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation. (Q46234389) (← links)
• Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome (Q48165705) (← links)
• Health values of patients with bipolar disorder (Q51969966) (← links)
• The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain (Q52048603) (← links)
• The health and activities limitation index in patients with acute myocardial infarction (Q52076849) (← links)
• Predicting patients' utilities from quality of life items: an improved scoring system for the UBQ-H. (Q52220340) (← links)
• Health profiles and health preferences of dialysis patients. (Q53458689) (← links)
• A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain (Q64097300) (← links)
• Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy (Q72413633) (← links)
• Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial (Q81428041) (← links)
• Cost-Effectiveness of Nucleoside Reverse Transcriptase Inhibitor Pairs in Efavirenz-Based Regimens for Treatment-Naïve Adults with HIV Infection in the United States (Q84757729) (← links)
• Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan (Q88495482) (← links)
• Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data (Q89637477) (← links)
• Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk (Q93157036) (← links)